|
A Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H For Previously Treated Relapsed or Refractory Patients with Chronic Lympocytic Leukemia. Diagnosis of B-CLL (Chronic Lymphocytic Leukemia (CLL) E2903)
- Patients must require chemotherapy, the last administration of chemotherapy must have been completed less than 6 weeks prior to study treatment.
- Patients must have demonstrated progression after at least one cycle of either alkylating agent based or purine nucleoside based regimen or failed to achieve a meaningful response, or relapsed after prior therapy.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion (EPO-ANE-3018):
- Male of Female at least 18 years of age
- Diagnosis of MDS, via bone marrow studies within 12 weeks of study entry
- Screening hemoglobin concentration of 10.0 g/dL
|
